![](https://danskbiotek.dk/wp-content/uploads/2021/02/scandion_oncology.jpg)
Scandion Oncology announces final data from the CORIST trial and is ready to move into a randomized phase II Proof of Concept trial in Colorectal Cancer 13 January 2025
Scandion Oncology, an innovative drug efflux pump inhibition company using biomodulation capability to... Read more